

November 27, 2013

## STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (AB-41) Pegargiminase

PRONUNCIATION peg" ar ji min' ase

THERAPEUTIC CLAIM Antineoplastic

## CHEMICAL NAME


1. pentakis(*N*-{4-[ $\omega$ -methoxypoly(oxyethylene)]-4-oxobutanoyl})-[111-glutamic acid,209-serine]arginine deiminase (ADI, arginine dihydrolase, AD) from *Mycoplasma hominis*
2. [111-glutamic acid,209-serine]arginine deiminase (ADI, arginine dihydrolase, AD) from *Mycoplasma hominis*, an average of five amino groups are amidified with 4-[ $\omega$ -methoxypoly(oxyethylene)]-4-oxobutanoyl

## STRUCTURAL FORMULA

## Amino Acid Sequence

<u>S</u> VFDS <u>K</u> FNGI	HVYSEIGELE	TVLVHEPGRE	IDYITPARLD	ELLFSAILES	50
HDAR <u>K</u> EHQSF	<u>V</u> <u>K</u> IM <u>K</u> DRGIN	VVELTDLVAE	TYDLAS <u>K</u> AA <u>K</u>	EEFIETFLEE	100
TVPVLTEAN <u>K</u>	EAVRAFLL <u>S</u> <u>K</u>	PTHEMVEFMM	SGIT <u>K</u> YELGV	ESENELIVDP	150
MPNLYFTRDP	FASVGN <u>G</u> VTI	HFMR <u>Y</u> IVRRR	ETLFARFVFR	NHP <u>K</u> LV <u>K</u> TPW	200
YDPA <u>M</u> MSI	EGGDVF <u>I</u> YNN	ETLVVGVSER	TDLDTITLLA	<u>K</u> NI <u>K</u> AN <u>K</u> EVE	250
<u>F</u> <u>K</u> RIVAINVP	<u>K</u> WTNLMHLDT	WLTMLD <u>K</u> <u>N</u> <u>K</u> F	LYSPIANUVF	<u>K</u> FWDYDLVNG	300
GAE <u>P</u> QQLNG	LPLD <u>K</u> LLASI	IN <u>K</u> EPVLIPI	GGAGATEMEI	ARETNFDGTN	350
YLAI <u>K</u> PGLVI	GYDRNE <u>K</u> TNA	AL <u>K</u> AAAGITVL	PFHGNQLSLG	MGNARCMSMP	400
LSR <u>K</u> DV <u>K</u> W					408

## Potential modified residues\*

\* an average of 5 (*a*) out of 28 are pegylatedMOLECULAR FORMULA  $\text{C}_{2091}\text{H}_{3276}\text{N}_{540}\text{O}_{607}\text{S}_{15} ((\text{C}_5\text{H}_6\text{O}_3(\text{C}_2\text{H}_4\text{O}))_n)_a$ MOLECULAR WEIGHT 146 kDa ( $a = 5$ ,  $n = 450$ )

TRADEMARK None as yet

SPONSOR Polaris Pharmaceuticals, Inc.

CODE DESIGNATIONS ADI-PEG20; ADI-PEG; ADI-SS; PEG 20,000

PEGARGIMINASE

Page 2 of 2

N13

138

CAS REGISTRY NUMBER 1394129-74-8

UNII 0B7PYQ9YRT

WHO NUMBER 9906

gbk